Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Debt to Equity (2016 - 2018)

Niagen Bioscience (NAGE) has disclosed Debt to Equity for 3 consecutive years, with $0.01 as the latest value for Q4 2018.

  • Quarterly Debt to Equity fell 12.46% to $0.01 in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $0.01 through Dec 2018, down 12.46% year-over-year, with the annual reading at $0.01 for FY2018, 12.46% down from the prior year.
  • Debt to Equity for Q4 2018 was $0.01 at Niagen Bioscience, down from $0.01 in the prior quarter.
  • The five-year high for Debt to Equity was $0.92 in Q1 2016, with the low at $0.01 in Q4 2018.
  • Average Debt to Equity over 3 years is $0.24, with a median of $0.02 recorded in 2016.
  • The sharpest move saw Debt to Equity crashed 96.27% in 2016, then decreased 12.46% in 2018.
  • Over 3 years, Debt to Equity stood at $0.03 in 2016, then plummeted by 83.3% to $0.01 in 2017, then dropped by 12.46% to $0.01 in 2018.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.01, $0.01, and $0.03 for Q4 2018, Q4 2017, and Q4 2016 respectively.